Oxford Expands Entellus Medical Facility
Oxford Finance announced it entered into a term loan agreement with Entellus Medical that expanded the original $17 million loan facility to $25 million. Proceeds will be used to support business operations and the ongoing marketing efforts for its minimally invasive treatments for chronic sinusitis.
“Entellus has impressed the medical community with its quality solutions for treating patients with sinusitis,” said Christopher A. Herr, managing director for Oxford Finance. “We are pleased to provide financial support to the company as it continues to grow revenues and increase market share.”
“Oxford has been a valued and reliable financial partner for Entellus,” said Thomas E. Griffin, CFO for Entellus Medical. “They understand our industry and support our primary business goal, which is to bring highly efficacious and cost-saving sinusitis treatments to patients in the convenience of the doctor’s office.”
Entellus Medical provides solutions for the minimally invasive treatment of chronic and recurrent sinusitis patients.